855230-60-3

Basic information

• Product Name: 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID
• Synonyms: 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID;2-Fluoro-3-hydroxybenzeneboronicacid96%
• CAS NO: 855230-60-3
• Molecular Formula: C₆H₆BFO₃
• Molecular Weight: 155.92
• Mol File: 855230-60-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID(855230-60-3)
• EPA Substance Registry System: 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID(855230-60-3)

Safety Data

• Hazardous Substances Data: 855230-60-3(Hazardous Substances Data)

Usage

General Description

2-Fluoro-3-hydroxyphenylboronic acid is a chemical compound that belongs to the class of boronic acids. It is a boronic acid derivative with a fluorine and a hydroxyl group attached to a phenyl ring. 2-FLUORO-3-HYDROXYPHENYLBORONIC ACID is commonly used in organic synthesis as a reagent for Suzuki-Miyaura cross-coupling reactions, which are important in the formation of carbon-carbon bonds. It can also be utilized as a building block for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. 2-Fluoro-3-hydroxyphenylboronic acid is an important intermediate in the synthesis of biologically active compounds and is valued for its versatility in organic chemistry.

Upstream product

• 352303-67-4 (2-fluoro-3-methoxyphenyl)boronic acid 

Downstream Products

• 1062642-64-1 {2-[5-(2-fluoro-3-hydroxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 873566-64-4 4-{3-[(N-tert-butoxycarbonylpiperidin-3-yl)carbonylamino]phenyl}-2-chloro-6-morpholinopyrimidine 

Relevant articles and documents

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER

The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their prep